MAITLAND, Fla. — October 7, 2025 — Leads & Copy — Global Innovative Platforms Inc. (OTC: GIPL) announced today the completion of the first phase of its research into breath-based diagnostics for detecting heartworm disease in dogs. The initial study included over 100 samples and focused on validating data to support development of a point-of-care, non-invasive test designed to detect infection earlier than the current industry standard of six months.
According to Andrew Brown, CEO of Global Innovative Platforms, early detection is key to protecting dogs from the serious effects of heartworm. The goal is to create a simple and non-invasive breath test that veterinary teams can use to potentially identify infections earlier than available heartworm diagnostic tests. If successful, earlier detection could enable veterinarians and owners the opportunity to intervene sooner, potentially helping dogs live healthier, longer lives.
Dr. Lindsay Starkey, DVM, PhD, DACVM, leading the research team at Global Innovative, stated that she is always looking for new ways to improve animal health. She added that working on this project is exciting, and the initial data is encouraging, and that she looks forward to continuing the research and exploring how breath analysis may contribute to earlier, more effective detection. Dr. Starkey worked alongside Drs. Byron Blagburn and Sarah Zohdy, both of whom were pioneers in the initial heartworm breath research starting in 2017. Additional on-site testing was overseen by parasitologist Dr. Elyssa Campbell, PhD, during the twelve-month study period. She commented that the data gathered show a lot of promise and reinforces their belief that breath analysis could be a significant step forward in veterinary diagnostics, and that she is grateful to be working with such a talented team and committed to continuing this work.
Global Innovative is planning further research seeking to confirm heartworm breath markers and expand testing. If successful, the company may pursue development of a proprietary diagnostic device with the goal of allowing for it to have the potential to detect multiple conditions through a single breath analysis.
Andrew Brown, CEO
Andrew@GIPLinc.com
321.230.3739
Source: Global Innovative Platforms Inc.
